New Hope for Diagnosis and Treatment of Intractable Pediatric Brain Tumors

Primitive neuroectodermal tumors (PNETs) arise from undifferentiated brain cells and are the most frequent malignant brain tumors in children. There are different forms of PNETs and, while scientists have made progress in characterizing the genetic abnormalities associated with some PNET subtypes, the highly aggressive cerebral tumors known as CNS-PNETs have been difficult to characterize as they represent a relatively uncommon group of tumors with ill-defined diagnostic features.

“Lack of insight into the molecular pathogenesis of CNS-PNET is a major obstacle towards development of disease-specific models and treatments for these frequently fatal malignancies,” explains senior study author, Dr. Annie Huang from the Hospital for Sick Children in Ontario, Canada. To comprehensively define relevant genetic alterations associated with CNS-PNET, Dr. Huang established international collaborations with colleagues from pediatric oncology centers in Asia, Europe and the United States to complete a sophisticated high resolution genomic screen of a large collection of primary tumors.

» Read more: New Hope for Diagnosis and Treatment of Intractable Pediatric Brain Tumors

Related posts

Types of Fibroids

A fibroid is a tumor or an abnormal growth that is benign. It is not associated with cancer, and they almost never develop into cancer. These fibroids can grow on the uterus and or the ovaries. One half of all women will have a fibroid, however, most probably won’t know it. That’s because most of them never cause any problems or symptoms. Occasionally a doctor may stumble upon one accidentally when doing a routine pelvic exam.

The 5 different types of fibroids are classified depending on their location. They are:

» Read more: Types of Fibroids

Related posts

Dendreon Rises After Winning Approval for Cancer Drug (Update2)

Dendreon Rises After Winning Approval for Cancer Drug (Update2)
April 29 (Bloomberg) — Dendreon Corp. won approval for its first product, a vaccine to fight prostate cancer, after a three-year battle with U.S. regulators. Shares surged the most in a year in New York trading.

Read more on Bloomberg

Related posts